Dermata Therapeutics, Inc. (DRMA)

Dermata Therapeutics Statistics

Total Valuation

DRMA has a market cap or net worth of $3.41 million. The enterprise value is -$3.43 million.

Market Cap	3.41M
Enterprise Value	-3.43M

Important Dates

The next estimated earnings date is Wednesday, November 12, 2025, after market close.

Earnings Date	Nov 12, 2025
Ex-Dividend Date	n/a

Share Statistics

DRMA has 681,557 shares outstanding. The number of shares has increased by 1,442.75% in one year.

Current Share Class	681,557
Shares Outstanding	681,557
Shares Change (YoY)	+1,442.75%
Shares Change (QoQ)	+23.72%
Owned by Insiders (%)	15.81%
Owned by Institutions (%)	2.73%
Float	498,471

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.51
P/TBV Ratio	0.54
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.47

Current Ratio	6.47
Quick Ratio	6.32
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -231.27% and return on invested capital (ROIC) is -147.48%.

Return on Equity (ROE)	-231.27%
Return on Assets (ROA)	-110.91%
Return on Invested Capital (ROIC)	-147.48%
Return on Capital Employed (ROCE)	-187.71%
Revenue Per Employee	n/a
Profits Per Employee	-$1.29M
Employee Count	8
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -66.55% in the last 52 weeks. The beta is 0.56, so DRMA's price volatility has been lower than the market average.

Beta (5Y)	0.56
52-Week Price Change	-66.55%
50-Day Moving Average	5.66
200-Day Moving Average	8.69
Relative Strength Index (RSI)	38.38
Average Volume (20 Days)	258,109

Short Selling Information

The latest short interest is 11,768, so 1.73% of the outstanding shares have been sold short.

Short Interest	11,768
Short Previous Month	13,002
Short % of Shares Out	1.73%
Short % of Float	2.36%
Short Ratio (days to cover)	0.39

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-10.54M
Pretax Income	-10.33M
Net Income	-10.33M
EBITDA	n/a
EBIT	-10.54M
Earnings Per Share (EPS)	-$16.20

Balance Sheet

The company has $6.48 million in cash and n/a in debt, giving a net cash position of $6.48 million or $9.51 per share.

Cash & Cash Equivalents	6.48M
Total Debt	n/a
Net Cash	6.48M
Net Cash Per Share	$9.51
Equity (Book Value)	5.61M
Book Value Per Share	8.80
Working Capital	5.61M

Cash Flow

Operating Cash Flow	-10.96M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

DRMA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1,442.75%
Shareholder Yield	-1,442.75%
Earnings Yield	-338.27%
FCF Yield	n/a

Analyst Forecast

The average price target for DRMA is $10.00, which is 100.00% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$10.00
Price Target Difference	100.00%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on August 1, 2025. It was a reverse split with a ratio of 1:10.

Last Split Date	Aug 1, 2025
Split Type	Reverse
Split Ratio	1:10

Scores

Altman Z-Score	n/a
Piotroski F-Score	1